Clinical trials
Chronic Hepatitis B Virus (HBV) Infection clinical trials
Below are recruiting chronic hepatitis b virus (hbv) infection clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07096193RecruitingPhase 1/Phase 2
Study of GS-4321 for chronic hepatitis delta
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
Anaheim, CaliforniaAges 18–69 - NCT07654283RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Palo Alto, CaliforniaAges 18–65 - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT07741461RecruitingPhase 1
Testing ACT201 for chronic hepatitis B
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT05403047RecruitingPhase 4
Preventing mom-to-baby hepatitis B with tenofovir
This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).
TokonbéréAges 16 years+ - NCT06876467Recruiting
Study of immune response to hepatitis B vaccine
This study looks at how your body's cells respond after getting a hepatitis B vaccine. It may help researchers understand how well the vaccine works.
ParisAges 18 years+ - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT07069569RecruitingPhase 2
AHB-137 injection combined with other hepatitis B drugs
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
Beijing, Beijing MunicipalityAges 18–65 - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07709520RecruitingPhase 2
Testing a new hepatitis B treatment in adults
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
BeijingAges 35–65 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT03097952Recruiting
Study of people with long-term hepatitis B in real life
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
Changzhou, JiangsuAges Any age - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT04843852RecruitingPhase 1
Test vaccine added to hepatitis B treatment
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Baltimore, MarylandAges 18 years+ - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT05392387Recruiting
Treatment and outcomes study for long-term hepatitis B
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Changsha, HunanAges 18–79 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05853718RecruitingPhase 4
Tenofovir treatment for hepatitis B during pregnancy
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hangzhou, ZhejiangAges 20–40 - NCT05856890RecruitingPhase 1
Test antibody treatment for chronic hepatitis B
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
New York, New YorkAges 18–70
Hear when a new Chronic Hepatitis B Virus (HBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis b virus (hbv) infection?
- Yes. Clin2 currently lists 72 recruiting chronic hepatitis b virus (hbv) infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis b virus (hbv) infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis b virus (hbv) infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.